SCHEMBL5649362

SCHEMBL5649362

O=c1ccc2c(ccn2-c2ccccc2)[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.59
CRBN Q96SW2 1/20 0.59
HCAR1 Q9BXC0 7/20 0.50
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA3 P07451 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA13 Q8N1Q1 1/20 0.41
CA14 Q9ULX7 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PARP1 P09874 1/20 0.40
MET P08581 1/20 0.39
COMT P21964 1/20 0.38
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1530734 0.75 CRBN (1.00) DDB1CRBNHCAR1SMN1; SMN2COMT
SCHEMBL11582074 0.70 DDB1 (0.69) DDB1CRBNHCAR1SMN1; SMN2MEN1
SCHEMBL4716268 0.70 HTR6 (0.53) METMEN1LMNAKMT2AL3MBTL1
SCHEMBL30763485 0.69 DDB1 (0.48) DDB1CRBNSMN1; SMN2COMTMEN1
SCHEMBL19239926 0.68 BRPF1 (0.42) CRBNHCAR1CA12CA1CA3
SCHEMBL19661133 0.67 DDB1 (0.49) DDB1CRBNHCAR1CA12CA9
SCHEMBL5649360 0.66 SMN1; SMN2 (0.46) DDB1CRBNSMN1; SMN2COMTMEN1
SCHEMBL7662776 0.64 COMT (0.49) DDB1CRBNSMN1; SMN2COMTL3MBTL1
SCHEMBL15213818 0.64 KIF11 (0.49) DDB1CRBNMEN1KMT2AL3MBTL1
SCHEMBL21666897 0.63 COMT (0.47) DDB1CRBNSMN1; SMN2COMTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 DDB1 522/4885CRBN 1089/4885HCAR1 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.